Similar articles

• Therapeutic drug monitoring of cyclosporine.

  Midtvedt K. Midtvedt K. Transplant Proc. 2004 Mar;36(2 Suppl):430S-433S. doi: 10.1016/j.transproceed.2004.01.025. Transplant Proc. 2004. PMID: 15041380 Review.
• Experience with conversion from Sandimmun to Neoral cyclosporine and the correlation of C2 levels with renal function.

  Konstadinidou I, Boletis JN. Konstadinidou I, et al. Transplant Proc. 2004 Mar;36(2 Suppl):163S-166S. doi: 10.1016/j.transproceed.2004.01.040. Transplant Proc. 2004. PMID: 15041329 Review.
• Cyclosporine neoral monitoring and its correlation with the "area under the curve".

  Sabbatiello R, Sgrosso JL, Schiavelli R, Castro C, Ahualli L, Pattin M, Vazquez MC. Sabbatiello R, et al. Transplant Proc. 1996 Dec;28(6):3378. Transplant Proc. 1996. PMID: 8962317 No abstract available.
• The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2.

  Cole E, Deshpande R. Cole E, et al. Transplant Proc. 2004 Mar;36(2 Suppl):408S-413S. doi: 10.1016/j.transproceed.2004.01.041. Transplant Proc. 2004. PMID: 15041376
• Therapeutic drug monitoring of cyclosporine.

  Jorga A, Holt DW, Johnston A. Jorga A, et al. Transplant Proc. 2004 Mar;36(2 Suppl):396S-403S. doi: 10.1016/j.transproceed.2004.01.013. Transplant Proc. 2004. PMID: 15041374 Review.